Lack of any relationship between chemotherapy toxicity in non-small cell lung cancer cases and polymorphisms in XRCC1 codon 399 or XPD codon 751.
To examine the association between genetic polymorphisms (at XRCC1codon 399 or XPD codon 751) and chemotherapy related toxicities of non-small cell lung cancer. One hundred and fifteen patients with histologically or cytologically confirmed stage IIIB and IV NSCLC recruited from Department of Chemotherapy of Jiangsu Cancer Hospital and Research Institute from 2005 to 2008, to evaluated the occurrence of chemotherapy related toxicities and the association with single nucleotide polymorphisms in XRCC1codon 399 or XPD codon 751. No significant association was observed between grade 0 or grade 1-4 overall toxicity and XRCC1 codon 399 (odds ratio=1.40, 95% confidence interval,0.73-2.66; adjusted odds ratio =1.43, 95% confidence interval,0.71-2.88), or XPD codon 751 genetic polymorphisms (odds ratio =0.87, 95% confidence interval,0.33-2.26; adjusted odds ratio=0.74, 95% confidence interval,0.26-2.13); similar results were found between hematologic, hepatic, gastrointestinal toxicities and XRCC1 399 or XPD 751 genetic polymorphisms. No statistically significant association was found between either XRCC1codon 399 or XPD codon 751 genetic polymorphisms and chemotherapy related toxicities.